MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027; ML-007C-MA holds FDA Fast Track d…